Systematic Review of Therapeutic Agents and Long-Term Outcomes of Familial Hyperaldosteronism Type 1.

Shu-Ting TanVeronica BoyleMarianne S Elston

Published in: Hypertension (Dallas, Tex. : 1979) (2023)

Major gaps in the literature around FH1 patients' long-term treatment and disease outcomes still exist. Long-term outcome data are required to help inform clinicians of the best long-term treatment for FH1.

Keyphrases

systematic review
end stage renal disease
chronic kidney disease
ejection fraction
randomized controlled trial
type diabetes
meta analyses
palliative care
prognostic factors
early onset
patient reported outcomes
artificial intelligence
combination therapy
big data
deep learning
replacement therapy
glycemic control